Matches in Nanopublications for { ?s ?p "[Antitumor effects of a soluble form dominant negative of the type I insulin-like growth factor receptor (IGF-IR) designated as 486/STOP were evaluated in CaOV-3 human ovarian cancer cells by establishing stable transformants overexpressing 486/STOP and by administration of 486/STOP recombinant protein.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- NP545921.RA5gvIEFeW0i0mrw4RpH38wma4rFIMtsETDqobYKx817g130_assertion description "[Antitumor effects of a soluble form dominant negative of the type I insulin-like growth factor receptor (IGF-IR) designated as 486/STOP were evaluated in CaOV-3 human ovarian cancer cells by establishing stable transformants overexpressing 486/STOP and by administration of 486/STOP recombinant protein.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP545921.RA5gvIEFeW0i0mrw4RpH38wma4rFIMtsETDqobYKx817g130_provenance.
- NP512828.RAyFhOfn2BrKRIHLl-lRenK_GyzucXCLVPHHdExfmFXMk130_assertion description "[Antitumor effects of a soluble form dominant negative of the type I insulin-like growth factor receptor (IGF-IR) designated as 486/STOP were evaluated in CaOV-3 human ovarian cancer cells by establishing stable transformants overexpressing 486/STOP and by administration of 486/STOP recombinant protein.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP512828.RAyFhOfn2BrKRIHLl-lRenK_GyzucXCLVPHHdExfmFXMk130_provenance.
- NP1008483.RAQkaMHUJeL-3RRqwoJLX_p1-a92eNxPfKrFHCM-2okOY130_assertion description "[Antitumor effects of a soluble form dominant negative of the type I insulin-like growth factor receptor (IGF-IR) designated as 486/STOP were evaluated in CaOV-3 human ovarian cancer cells by establishing stable transformants overexpressing 486/STOP and by administration of 486/STOP recombinant protein.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1008483.RAQkaMHUJeL-3RRqwoJLX_p1-a92eNxPfKrFHCM-2okOY130_provenance.
- NP421699.RAzZXILzFXIrG9hXyNgvRpAqP3dS89TPoiJWAeP8cdkwA130_assertion description "[Antitumor effects of a soluble form dominant negative of the type I insulin-like growth factor receptor (IGF-IR) designated as 486/STOP were evaluated in CaOV-3 human ovarian cancer cells by establishing stable transformants overexpressing 486/STOP and by administration of 486/STOP recombinant protein.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP421699.RAzZXILzFXIrG9hXyNgvRpAqP3dS89TPoiJWAeP8cdkwA130_provenance.
- NP421700.RAXxBldou5AVYtZ_6gIyHRiSkzhwAI3ZX9gvscyOUhUrE130_assertion description "[Antitumor effects of a soluble form dominant negative of the type I insulin-like growth factor receptor (IGF-IR) designated as 486/STOP were evaluated in CaOV-3 human ovarian cancer cells by establishing stable transformants overexpressing 486/STOP and by administration of 486/STOP recombinant protein.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP421700.RAXxBldou5AVYtZ_6gIyHRiSkzhwAI3ZX9gvscyOUhUrE130_provenance.
- assertion description "[Antitumor effects of a soluble form dominant negative of the type I insulin-like growth factor receptor (IGF-IR) designated as 486/STOP were evaluated in CaOV-3 human ovarian cancer cells by establishing stable transformants overexpressing 486/STOP and by administration of 486/STOP recombinant protein.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Antitumor effects of a soluble form dominant negative of the type I insulin-like growth factor receptor (IGF-IR) designated as 486/STOP were evaluated in CaOV-3 human ovarian cancer cells by establishing stable transformants overexpressing 486/STOP and by administration of 486/STOP recombinant protein.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP545935.RAF3l3ipqRox66SU_2iCzzsPEzQxLa0jc0gt5WxHrdBCE130_assertion description "[Antitumor effects of a soluble form dominant negative of the type I insulin-like growth factor receptor (IGF-IR) designated as 486/STOP were evaluated in CaOV-3 human ovarian cancer cells by establishing stable transformants overexpressing 486/STOP and by administration of 486/STOP recombinant protein.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP545935.RAF3l3ipqRox66SU_2iCzzsPEzQxLa0jc0gt5WxHrdBCE130_provenance.
- NP511493.RApp_q6vB5LpOEpZ_QCCAZDcY0OcsSTqEoL8N2BT1LF9I130_assertion description "[Antitumor effects of a soluble form dominant negative of the type I insulin-like growth factor receptor (IGF-IR) designated as 486/STOP were evaluated in CaOV-3 human ovarian cancer cells by establishing stable transformants overexpressing 486/STOP and by administration of 486/STOP recombinant protein.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP511493.RApp_q6vB5LpOEpZ_QCCAZDcY0OcsSTqEoL8N2BT1LF9I130_provenance.
- NP421703.RAK20wcvrqq0MuYm65vG9K31eyVbA-BeEdJF-acT_kHXQ130_assertion description "[Antitumor effects of a soluble form dominant negative of the type I insulin-like growth factor receptor (IGF-IR) designated as 486/STOP were evaluated in CaOV-3 human ovarian cancer cells by establishing stable transformants overexpressing 486/STOP and by administration of 486/STOP recombinant protein.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP421703.RAK20wcvrqq0MuYm65vG9K31eyVbA-BeEdJF-acT_kHXQ130_provenance.
- NP1007201.RArI5KDTRrAHc5j8CenNf_jbDw8GdO9mDi4EaKVLkiZr8130_assertion description "[Antitumor effects of a soluble form dominant negative of the type I insulin-like growth factor receptor (IGF-IR) designated as 486/STOP were evaluated in CaOV-3 human ovarian cancer cells by establishing stable transformants overexpressing 486/STOP and by administration of 486/STOP recombinant protein.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1007201.RArI5KDTRrAHc5j8CenNf_jbDw8GdO9mDi4EaKVLkiZr8130_provenance.
- NP421701.RAo2D8Lhwx2AcG3G6WCA_qAEWcvvUQeWek3fASvPSmQoI130_assertion description "[Antitumor effects of a soluble form dominant negative of the type I insulin-like growth factor receptor (IGF-IR) designated as 486/STOP were evaluated in CaOV-3 human ovarian cancer cells by establishing stable transformants overexpressing 486/STOP and by administration of 486/STOP recombinant protein.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP421701.RAo2D8Lhwx2AcG3G6WCA_qAEWcvvUQeWek3fASvPSmQoI130_provenance.